Safety of MF-59 adjuvanted vaccine for pandemic influenza: Results of the vaccination campaign in an Italian health district

Vaccine

Volumn 29, Issue 18, 2011, Pages 3443-3448

  Cristiani, Cristina ^a   Tuccori, Marco ^b,c   Pepe, Pasquale ^d   Sarteschi, Alessandro ^a   Maddalo, Francesco ^e   Simonini, Gianmarco ^f   Michi, Paola ^g   Consigli, Veronica ^a   Fornai, Matteo ^h   Antonioli, Luca ^h   Blandizzi, Corrado ^b,h  

^a Health District of La Spezia   (Italy)

^b Tuscan Regional Centre of Pharmacovigilance   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^e University of Pisa ^*  (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Unit of Pediatrics   (Italy)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

Adverse events; MF59; Pandemic influenza; Safety

Indexed keywords

ADIUGRIP; INFLUENZA VACCINE; ISIFLU; MIFAMURTIDE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; APPETITE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; BODY WEIGHT; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONJUNCTIVITIS; COUGHING; DERMATITIS; DIARRHEA; DISORIENTATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; EXTERNAL OTITIS; EYE INFLAMMATION; FACE EDEMA; FATIGUE; FEMALE; FOLLOW UP; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEADACHE; HEALTH CENTER; HEALTH PROGRAM; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERPYREXIA; INFANT; INFECTION SENSITIVITY; INJECTION SITE REACTION; INSOMNIA; ITALY; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MUCOSAL DRYNESS; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OTALGIA; PARESTHESIA; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATITIS; RAYNAUD PHENOMENON; RESPIRATORY TRACT INFECTION; RHINITIS; RISK ASSESSMENT; SCHOOL CHILD; SEASONAL INFLUENZA; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STROKE; SYNCOPE; TINNITUS; TREMOR; UPPER ABDOMINAL PAIN; VACCINATION; VERTIGO; VOMITING;

ADULT; AGED; ARTHRALGIA; CHILD; CHILD, PRESCHOOL; FATIGUE; FEMALE; HEADACHE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ITALY; MALE; MIDDLE AGED; POLYSORBATES; PREGNANCY; PROSPECTIVE STUDIES; SQUALENE; VACCINATION;

EID: 79954904232     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.068     Document Type: Article

References (25)

1. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in Humans. N Engl J Med 2009, 360:2605-2615.
2. Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol 2009, 45:174-178.
3. Peiris J.S., Poon L.L., Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009, 45:169-173.
4. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009, 84:249-257.
5. Smith G.J., Bahl J., Vijaykrishna D., Zhang J., Poon L.L., Chen H., et al. Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci USA 2009, 106:11709-11712.
6. European Medicinal Agency. Questions and answers on " mock-up" pandemic flu vaccine. Available from: [accessed 29.01.11]. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014641.pdf.
7. Wu j, Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., et al. Immunogenicity, safety, and cross-reactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009, 48:1087-1095.
8. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009, 4:e4384.
9. Strategic advisory group of experts on immunization-report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol Rec 2009;84:301-8. Available from: [accessed 29.01.11]. http://www.who.int/wer/2009/wer8430.pdf.
10. [accessed 29.01.11]. http://www.emea.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/000710/WC500023749.pdf.
11. Available from: [accessed 24.06.10; 29.01.11]. http://www.emea.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500044933.pdf.
12. Use of influenza A (H1N1) 2009 monovalent vaccines: recommendation of the advisory committee of immunization practices (ACIP) 2009. MMWR 2009;58:1-8. Available from: [accessed 18.10.10; 29.01.11]. http://www.cdc.gov/mmwr/pdf/rr/rr58e0821.pdf.
13. Availability of a candidate reassortant vaccine virus for the novel Influenza A (H1N1) vaccine development X-179A. Available from: [accessed 29.01.11]. http://www.who.int/csr/resources/publications/swineflu/2009_05_27_X179Aa.pdf.
14. Recommendation for the composition of influenza virus vaccines for use in the 2009/2010 season in the northern hemisphere. Wkly Epidemiol Rec 2009;84:65-76. Available from: [accessed 29.01.11]. http://www.who.int/csr/disease/influenza/recommendations2009_10north/en/index.html.
15. Available from: [accessed 31.01.11]. http://www.farmacovigilanza.org/legislazione/DLgs_N219.pdf.
16. Lu C.Y., Shao P.L., Chang L.Y., Huang Y.C., Chiu C.H., Hsieh Y.C., et al. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A(H1N1) in children and adolescents. Vaccine 2010, 28:5864-5870.
17. Lim S.H., Lee J.H., Kim B.C., Jung S.U., Park Y.B., Lee C.S. Adverse reaction of influenza A (H1N1) 2009 virus vaccination in pregnant women and its effect on newborns. Vaccine 2010, 28:7455-7456.
18. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nasch D., et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998, 339:1797-1802.
19. Juurlink D.N., Stukel T.A., Kwong J., Kopp A., McGeer A., Upshur D.G., et al. Guillan-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006, 166:2217-2221.
20. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine, United States, 2009-2010. Available from: [accessed 02.06.10; 29.01.11]. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm59e0602a1.htm.
21. Ministero della Salute 31 DICEMBRE Comunicato n. 618 Influenza A/H1N1 Il punto della situazione alla settimana 52 (21-27 dicembre) Available from: [accessed 10.09.10; 29.01.11]. http://www.salute.gov.it/imgs/C_17_comunicati_2684_testo.rtf.
22. Australian Government, Department of Health and Ageing. Australian surveillance influenza summary report, No. 19, 2009. Available from: [accessed 18.10.10; 29.01.11]. http://www.healthemergency.gov.au/internet/healthemergency/publishing.nsf/Content/18D06BAC4644C98DCA25763E00823442/$File/ozflu-no19-2009.pdf.
23. Available from: [accessed 18.10.10; 29.01.11]. http://www.epicentro.iss.it/focus/h1n1/pdf/flunews/FluNews_19.pdf.
24. Available from: [accessed 18.10.10; 29.01.11]. http://www.epicentro.iss.it/focus/h1n1/pdf/flunews/FluNews_4.pdf.
25. Lippi G., Targher G., Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction?. Eur J Intern Med 2010, 21:70-73.